The 5-LOX Pathway vs COX-1/COX-2
Most standard anti-inflammatory drugs inhibit cyclooxygenase (COX) enzymes, which can erode stomach lining. In peripheral neuropathy, however, the primary chemical mediators of sensory hypersensitivity are leukotrienes produced via the 5-lipoxygenase (5-LOX) pathway. Boswellia specifically targets 5-LOX without disrupting protective gastric prostaglandins.
Calming Nocturnal Sensory Flare-Ups
Leukotriene concentrations tend to peak during evening circadian cycles, explaining why neuropathic burning and prickling sensations frequently intensify when resting in bed. By dampening 5-LOX signaling, Boswellia provides sustained nighttime comfort.
Clinical Trial Evidence in Humans
Double-blind placebo-controlled human trials document significant reductions in localized tissue sensitivity, swelling, and joint stiffness within 30 to 60 days of standardized Boswellia administration.